Withdrawn: Reduced Risk of Recurrence of Noninfectious Posterior Segment Uveitis After 0.18-mg Fluocinolone Acetonide Insert: Randomized Trial

Affiliations

¹ Texas Retina Associates, Arlington, Texas, USA; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
² Byers Eye Institute, Stanford University, Palo Alto, California, USA.
³ Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA; Department of Public Health, Oregon Health and Science University-Portland State University School of Public Health, Portland, Oregon, USA; Ophthalmology Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
⁴ EyePoint Pharmaceuticals, Inc, Watertown, Massachusetts, USA.

David Callanan et al. Am J Ophthalmol. 2020.

. 2020 Feb 20:S0002-9394(20)30064-7.

doi: 10.1016/j.ajo.2020.02.011. Online ahead of print.

¹ Texas Retina Associates, Arlington, Texas, USA; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
² Byers Eye Institute, Stanford University, Palo Alto, California, USA.
³ Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA; Department of Public Health, Oregon Health and Science University-Portland State University School of Public Health, Portland, Oregon, USA; Ophthalmology Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
⁴ EyePoint Pharmaceuticals, Inc, Watertown, Massachusetts, USA.

Retraction in

No abstract available